Matching articles for "Requip"

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • February 22, 2021;  (Issue 1618)
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems. No disease-modifying drugs are available for treatment of PD.
Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32 | Show Full IntroductionHide Full Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • February 22, 2021;  (Issue 1618)
...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2021 Feb 22;63(1618):e1-9 | Show Full IntroductionHide Full Introduction

Istradefylline (Nourianz) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • February 10, 2020;  (Issue 1591)
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience...
The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor antagonist to be approved in the US; it has been available in Japan since 2013.
Med Lett Drugs Ther. 2020 Feb 10;62(1591):20-3 | Show Full IntroductionHide Full Introduction

Osmolex ER - Another Extended-Release Amantadine for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • September 10, 2018;  (Issue 1555)
The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms...
The FDA has approved an extended-release tablet formulation of amantadine (Osmolex ER – Vertical/Osmotica) for once-daily treatment of Parkinson's disease (PD) and drug-induced extrapyramidal symptoms (EPS) in adults. An extended-release capsule formulation of amantadine (Gocovri) was approved in 2017 for treatment of levodopa-induced dyskinesia in patients with PD.
Med Lett Drugs Ther. 2018 Sep 10;60(1555):148-50 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 20, 2017;  (Issue 1534)
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused...
The motor symptoms of Parkinson's disease (PD) are caused primarily by degeneration of dopaminergic neurons in the substantia nigra. The nonmotor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Med Lett Drugs Ther. 2017 Nov 20;59(1534):187-94 | Show Full IntroductionHide Full Introduction

Comparison Table: Drugs for Parkinson's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • November 20, 2017;  (Issue 1534)
...
View the Comparison Table: Drugs for Parkinson's Disease
Med Lett Drugs Ther. 2017 Nov 20;59(1534):e194-6 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 1, 2013;  (Issue 135)
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be...
The motor symptoms of Parkinson's disease (PD) are caused primarily by progressive degeneration of dopaminergic neurons in the substantia nigra. The non-motor symptoms of the disease are thought to be caused by degeneration of other neurotransmitter systems.
Treat Guidel Med Lett. 2013 Nov;11(135):101-6 | Show Full IntroductionHide Full Introduction

In Brief: Transdermal Rotigotine (Neupro)

   
The Medical Letter on Drugs and Therapeutics • August 20, 2012;  (Issue 1397)
A patch formulation of the non-ergot dopamine agonist rotigotine (Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early...
A patch formulation of the non-ergot dopamine agonist rotigotine (Neupro – UCB) has returned to the US market after a 4-year absence. Originally approved by the FDA in 2007 for treatment of early Parkinson’s disease,1 it was withdrawn in 2008 because of crystallization of the drug in the patch, which could have led to under-dosing. The new patch has somewhat broader indications than the old one; it is approved for use in any stage of Parkinson’s disease (PD) and also for moderate-to-severe restless legs syndrome (RLS).

1. Transdermal rotigotine (Neupro) for Parkinson’s disease. Med Lett Drugs Ther 2007; 49:69.

Download complete U.S. English article

Med Lett Drugs Ther. 2012 Aug 20;54(1397):68 | Show Full IntroductionHide Full Introduction

Gabapentin Enacarbil (Horizant) for Restless Legs Syndrome

   
The Medical Letter on Drugs and Therapeutics • September 5, 2011;  (Issue 1372)
Gabapentin enacarbil (Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs...
Gabapentin enacarbil (Horizant – GlaxoSmithKline), a new extended-release (ER) tablet formulation of gabapentin, has been approved by the FDA for treatment of moderate-to-severe restless legs syndrome (RLS). The immediate-release (IR) formulation of gabapentin (Neurontin,and others), which is approved for treatment of epilepsy and postherpetic neuralgia, has been used for many years to treat RLS. Another ER tablet formulation of gabapentin (Gralise) has been approved by the FDA for treatment of postherpetic neuralgia.
Med Lett Drugs Ther. 2011 Sep 5;53(1372):70-1 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • January 1, 2011;  (Issue 101)
Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the...
Parkinson’s disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the blood-brain barrier.
Treat Guidel Med Lett. 2011 Jan;9(101):1-6 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • October 1, 2007;  (Issue 62)
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the...
ParkinsonÆs disease (PD) is caused primarily by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat PD because it does not cross the bloodbrain barrier.
Treat Guidel Med Lett. 2007 Oct;5(62):89-94 | Show Full IntroductionHide Full Introduction

Transdermal Rotigotine (Neupro) for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • August 27, 2007;  (Issue 1268)
Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease...
Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
Med Lett Drugs Ther. 2007 Aug 27;49(1268):69-70 | Show Full IntroductionHide Full Introduction

Pramipexole (Mirapex) for Restless Leg Syndrome

   
The Medical Letter on Drugs and Therapeutics • March 26, 2007;  (Issue 1257)
The dopamine agonist pramipexole (Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip), another dopamine...
The dopamine agonist pramipexole (Mirapex - Boehringer Ingelheim) is the second drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS). Ropinirole (Requip), another dopamine agonist, was approved for RLS in 2005. Both of these drugs were first approved for treatment of Parkinson's disease.
Med Lett Drugs Ther. 2007 Mar 26;49(1257):26-8 | Show Full IntroductionHide Full Introduction

Ropinirole for Restless Legs Syndrome

   
The Medical Letter on Drugs and Therapeutics • August 1, 2005;  (Issue 1214)
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs...
Ropinirole (Requip - GlaxoSmithKline), a dopamine agonist already available for treatment of Parkinson's disease, is now the first drug approved by the FDA for treatment of moderate to severe restless legs syndrome (RLS).
Med Lett Drugs Ther. 2005 Aug 1;47(1214):62-4 | Show Full IntroductionHide Full Introduction

Drugs for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • June 1, 2004;  (Issue 22)
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the...
Parkinson's disease is caused by progressive degeneration of dopamine-containing neurons in the substantia nigra. Dopamine itself cannot be used to treat Parkinson's disease because it does not cross the blood-brain barrier.
Treat Guidel Med Lett. 2004 Jun;2(22):41-6 | Show Full IntroductionHide Full Introduction

Initial Treatment of Parkinson's Disease:Wait Just a Minute

   
The Medical Letter on Drugs and Therapeutics • July 9, 2001;  (Issue 1108)
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial...
Recent articles in the press have trumpeted a new era in the management of Parkinson's disease: dopamine agonists have now replaced levodopa for initial treatment.
Med Lett Drugs Ther. 2001 Jul 9;43(1108):59-60 | Show Full IntroductionHide Full Introduction

Pramipexole and Ropinirole for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • November 21, 1997;  (Issue 1014)
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early...
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early (without levodopa) and advanced (with levodopa) Parkinson's disease. Bromocriptine (Parlodel) and pergolide (Permax) are older dopamine agonists marketed in the USA for adjunctive use with levodopa.
Med Lett Drugs Ther. 1997 Nov 21;39(1014):109-10 | Show Full IntroductionHide Full Introduction